Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to ...

According to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for treating idiopathic pulmonary fibrosis (IPF). The trial’s primary objective ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, and Qureight Ltd, a Core Imaging Laboratory with ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendation by the trial’s independent Data Safety ...

IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis, it is ...